Abstract
Mast cells function as the initiator of the allergic reaction and play a role in the innate immune system. Aggregation of the high affinity IgE receptor (FcεRI) on mast cells triggers degranulation with the release of chemical mediators such as histamine, production of cytokines and leukotrienes. FcεRI signals by activating proximal non-receptor type of protein-tyrosine kinases, Lyn, Syk, Btk and Fyn. Activated tyrosine kinases then phosphorylate their specific substrates which include other enzymes and adaptor proteins and assemble these cytoplasmic signaling molecules for cellular activation. The adaptor proteins have multiple domains that allow binding to effector molecules and therefore act as positive or negative regulators controlling FcεRI signaling. Deletion of the adaptor proteins such as LAT, SLP-76 or Gab2 resulted in decreased FcεRI-mediated anaphylactic reaction in vivo. Functional analysis of adaptor proteins has raised the possibility that they may be new targets for the discovery of anti-allergic drugs.
Keywords: protein tyrosine kinases, adaptor protein, mediated, mast cells, ige receptor, lyn, src family
Current Molecular Medicine
Title: Protein-Tyrosine Kinases and Adaptor Proteins in FcεRI-Mediated Signaling in Mast Cells
Volume: 3 Issue: 1
Author(s): Kiyonao Sada and Hirohei Yamamura
Affiliation:
Keywords: protein tyrosine kinases, adaptor protein, mediated, mast cells, ige receptor, lyn, src family
Abstract: Mast cells function as the initiator of the allergic reaction and play a role in the innate immune system. Aggregation of the high affinity IgE receptor (FcεRI) on mast cells triggers degranulation with the release of chemical mediators such as histamine, production of cytokines and leukotrienes. FcεRI signals by activating proximal non-receptor type of protein-tyrosine kinases, Lyn, Syk, Btk and Fyn. Activated tyrosine kinases then phosphorylate their specific substrates which include other enzymes and adaptor proteins and assemble these cytoplasmic signaling molecules for cellular activation. The adaptor proteins have multiple domains that allow binding to effector molecules and therefore act as positive or negative regulators controlling FcεRI signaling. Deletion of the adaptor proteins such as LAT, SLP-76 or Gab2 resulted in decreased FcεRI-mediated anaphylactic reaction in vivo. Functional analysis of adaptor proteins has raised the possibility that they may be new targets for the discovery of anti-allergic drugs.
Export Options
About this article
Cite this article as:
Sada Kiyonao and Yamamura Hirohei, Protein-Tyrosine Kinases and Adaptor Proteins in FcεRI-Mediated Signaling in Mast Cells, Current Molecular Medicine 2003; 3 (1) . https://dx.doi.org/10.2174/1566524033361618
DOI https://dx.doi.org/10.2174/1566524033361618 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Pluripotential Effects of Hypolipidemic Treatment for Polycystic Ovary Syndrome (PCOS): Dyslipidemia, Cardiovascular Risk Factors and Beyond
Current Pharmaceutical Design Cannabinoids
Current Drug Targets - CNS & Neurological Disorders Infection, its Treatment and the Risk for Stroke
Current Vascular Pharmacology Current Advances in L-DOPA and DOPA-Peptidomimetics: Chemistry, Applications and Biological Activity
Current Medicinal Chemistry Biologic Therapy in Inflammatory and Immunomediated Skin Diseases: Safety Profile
Current Drug Safety CB1 Cannabinoid Antagonists: Structure-Activity Relationships and Potential Therapeutic Applications
Current Topics in Medicinal Chemistry Nitric Oxide and Dietary Factors: Part V Summary/Conclusion and References
Vascular Disease Prevention (Discontinued) Current Concepts for Optimizing the Therapeutic Index of Glucocorticoid Receptor Ligands for Oral and Inhalative Use: Basic Considerations and Clinical Reality
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Removing Protein Aggregates: The Role of Proteolysis in Neurodegeneration
Current Medicinal Chemistry The Role of Cytochrome P450 Enzymes in the Metabolism of Risperidone and Its Clinical Relevance for Drug Interactions
Current Drug Targets Immunophilins: Structures, Mechanisms and Ligands
Current Molecular Pharmacology Special Invited Article Concussion, Sports and Psychiatry
Adolescent Psychiatry Human Embryonic and Induced Pluripotent Stem Cell Based Toxicity Testing Models: Future Applications in New Drug Discovery
Current Medicinal Chemistry Immune Frailty and Nanomaterials: The Case of Allergies
Current Bionanotechnology (Discontinued) Conventional and Gene Therapy Strategies for the Treatment of Brain Tumors
Current Medicinal Chemistry Cannabinoids and Cardiovascular Disease: The Outlook for Clinical Treatments
Current Vascular Pharmacology Anticoagulant Therapy in Pregnant Patients with Metabolic Syndrome: A Review
Current Pharmaceutical Biotechnology Entry Inhibitors Directed Towards Glycoprotein gp120: An Overview on a Promising Target for HIV-1 Therapy
Current Medicinal Chemistry Skeletal Effects of Systemic and Topical Corticosteroids
Current Drug Safety Biotherapy for Autoimmune Liver Diseases
Current Pharmaceutical Biotechnology